Real-World Perspectives on the Role of TYK2 Inhibitors in the Treatment of PsoriasisExpert Perspectives
How are TYK2 inhibitors different from conventional JAK inhibitors? In what patient population would they be best suited? Find out in this expert-led clinical review and panel discussion that provides the knowledge you need on the investigational TYK2 inhibitors and their potential roles in personalized psoriasis treatment plans. This content is available across two modules, allowing you to choose where to focus your time.
Faculty: April Armstrong, MD, MPH; Neal Bhatia, MD; Mark Lebwohl, MD
Expiration Date: September 30, 2022
CME/CE is no longer available for this activity